Title: | The Successful Retreatment with Glecaprevir and Pibrentasvir of Genotype 1 or 2 HCV-infected Hemodialysis Patients who Failed to Respond to NS5A and Protease Inhibitor Treatment |
Authors: | Suda, Goki Browse this author →KAKEN DB |
Nakai, Masato Browse this author |
Sho, Takuya Browse this author |
Kimura, Megumi Browse this author |
Shimazaki, Tomoe Browse this author |
Maehara, Osamu Browse this author |
Shigesawa, Taku Browse this author |
Suzuki, Kazuharu Browse this author |
Nakamura, Akihisa Browse this author |
Ohara, Masatsugu Browse this author |
Umemura, Machiko Browse this author |
Kawagishi, Naoki Browse this author |
Baba, Masaru Browse this author |
Natsuizaka, Mitsuteru Browse this author →KAKEN DB |
Morikawa, Kenichi Browse this author |
Ogawa, Koji Browse this author →KAKEN DB |
Sakamoto, Naoya Browse this author →KAKEN DB |
Keywords: | HCV |
retreatment |
glecaprevir |
pibrentasvir |
hemodialysis |
Issue Date: | 1-Apr-2019 |
Publisher: | 日本内科学会 |
Journal Title: | Internal medicine |
Volume: | 58 |
Issue: | 7 |
Start Page: | 943 |
End Page: | 947 |
Publisher DOI: | 10.2169/internalmedicine.2077-18 |
PMID: | 30568153 |
Abstract: | Clinical trials and real-world data have proven that hepatitis C virus (HCV) in most infected patients can be eradicated by direct-acting antivirals (DAAs). However, the proper retreatment regimen for hemodialysis patients with HCV infection who have previously failed to respond to DAAs has not been clarified. We herein report, for the first time, the successful retreatment with glecaprevir and pibrentasvir, of three hemodialysis patients with genotype 1 or 2 HCV infection, who had previously failed to respond to combination therapy with an HCV-NA5A inhibitor (daclatasvir) and an HCV protease inhibitor (asunaprevir). |
Rights: | https://creativecommons.org/licenses/by-nc-nd/4.0/ |
Type: | article |
URI: | http://hdl.handle.net/2115/74043 |
Appears in Collections: | 北海道大学病院 (Hokkaido University Hospital) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)
|